CD4 and myeloid sarcoma: Interestingly, among the T cell subsets showing significant alterations during fingolimod therapy, only the CD4+TCM percentages were associated with MS relapse, although the pre-treatment TCM percentages in CD4+T cells did not differ significantly between the relapsed and non-relapsed patients, suggesting a critical role of CD4+TCM cells in MS relapse.